Project Grant R01CA299335
Award Date 9/23/25
Completion Date 8/31/29
Dollars Obligated $2.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Oregon, USA
Similar Awards
- This federal Project Grant award of $1,525,292 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports a research project led by Oregon Health & Science University (OHSU) to characterize the progression of prostate cancer through integrated analysis of single-cell data. The project, which commenced on September 30, 2024 and is scheduled for completion by September 29, 2027, aims to advance the understanding of prostate cancer biology and...
- This $564,543 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research federal grant program (CFDA 93.393). The grant supports research at the Weill Medical College of Cornell University to investigate how the androgen receptor (AR) governs normal, growth-suppressive gene expression in prostate cells, and how this program becomes hijacked to drive oncogenic transcription in prostate cancer. The research aims to determine if the normal,...
- This $112,230 federal Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to The University of Texas M.D. Anderson Cancer Center will support research to evaluate the potential of Type 1 conventional dendritic cell (CDC1) vaccination, alone and in combination with anti-CTLA4 immune checkpoint blockade, to induce antigen spread and generate diverse, effective CD8+ T cell responses against melanoma tumors. The project aims to study the ability of CDC1...
- The National Cancer Institute (NCI) awarded a $535,334 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Albert Einstein College of Medicine to conduct research on the non-autonomous role of androgen signaling in prostate tumorigenesis. The project aims to investigate how androgen receptor (AR) activation in prostatic stromal cells, specifically those expressing the GLI1 transcription factor, can promote prostate epithelial oncogenesis and tumor development through paracrine signaling...
- This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $245,472 to Duke University to study the role of the androgen receptor (AR) in hepatocellular carcinoma (HCC), the third leading cause of cancer death in the U.S. The project aims to: 1) measure the effect of AR signaling on the oncogenic traits of HCC models, 2) define the transcriptional profile of AR in HCC, and 3) determine the therapeutic potential of AR inhibition in...
- This federal Project Grant award of $663,340 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to elucidate the mechanisms by which the ablation of intratumoral regulatory T cells can mobilize NK cells and CD4 T cells to control MHC I-deficient tumors. The research aims to determine how CD4 T cell help enhances the antitumor function of NK cells, including the role of cytokines like IL-2 and IL-15, as well as test whether intratumoral Treg depletion...
- This $2,131,064 federal Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to the University of Colorado-Denver supports research on the effects of androgen receptors in luminal breast cancer. The four-year project, titled "ANDROGEN RECEPTORS IN LUMINAL BREAST CANCER: EFFECTS ON RESPONSE TO ENDOCRINE THERAPY AND AN IMMUNE-SUPPRESSIVE TUMOR IMMUNE MICROENVIRONMENT (TIME)", aims to investigate how androgen receptor...
- This federal Project Grant award in the amount of $1,229,700.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is supporting research conducted by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts focused on "DISSECTION OF MOLECULAR ASSOCIATIONS OF RESPONSE TO NEOADJUVANT ANTIANDROGEN THERAPIES IN HIGH-RISK LOCALIZED PROSTATE CANCER." The 4-year research project aims to advance the...
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- The National Cancer Institute awarded a 5-year, $632,906 Project Grant to Tulane University under the Cancer Biology Research federal grant program (CFDA 93.396). The grant aims to elucidate a novel role for the androgen receptor (AR) in promoting prostate cancer progression and therapeutic resistance through its RNA-binding activity. Specifically, the research will investigate how AR binds to and regulates the expression of key splicing factors, leading to efficient splicing and expression of...